Tags

Type your tag names separated by a space and hit enter

Specific Susceptibility to COVID-19 in Adults with Down Syndrome.
Neuromolecular Med. 2021 Mar 04 [Online ahead of print]NM

Abstract

The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer's disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.

Authors+Show Affiliations

The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, 5290002, Ramat-Gan, Israel. The Paul Feder Laboratory On Alzheimer's Disease Research, Bar-Ilan University, 5290002, Ramat-Gan, Israel.Laboratory of Molecular Biology and Immunology, NIA, Baltimore, MD, 21224, USA.Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.Leumit Health Services, Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.Leumit Health Services, Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain. Alzheimer-Down Unit, Fundación Catalana Síndrome de Down, Barcelona, Spain.Department of Anatomy and Cell Biology, McGill University, Montreal, Canada.Cellular & Systems Neurobiology, Systems Biology Program, The Barcelona Institute of Science and Technology, Centre for Genomic Regulation (CRG), Dr. Aiguader 88, 08003, Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.Cellular & Systems Neurobiology, Systems Biology Program, The Barcelona Institute of Science and Technology, Centre for Genomic Regulation (CRG), Dr. Aiguader 88, 08003, Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.School of Education, Bar-Ilan University, 5290002, Ramat-Gan, Israel.Department of Genetic Medicine and Development, University of Geneva, 1211, Geneva, Switzerland. Medigenome, Swiss Institute of Genomic Medicine, 1207, Geneva, Switzerland. iGE3 Institute of Genetics and Genomics of Geneva, 1211, Geneva, Switzerland.The Children's Guild Foundation Down Syndrome Research Program, Genetics and Genomics Program and Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Genetics, Genomics and Bioinformatics Program, State University of New York At Buffalo, Buffalo, NY, USA.Université de Strasbourg, CNRS, INSERM, Institut de Génétique Biologie Moléculaire Et Cellulaire, IGBMC-UMR, 7104 - Inserm U1258, 1 rue Laurent Fries, ILLKIRCH, 67404, Cedex, France.Paris Brain Institute (ICM), CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de La Pitié-Salpêtrière, Paris, France.Paris Brain Institute (ICM), CNRS UMR7225, INSERM U1127, Sorbonne Université, Hôpital de La Pitié-Salpêtrière, Paris, France.Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, USA.The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel.The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel.Université de Paris, BFA, UMR 8251, CNRS, 7501, Paris, France.Department of Neurosciences, University of California, San Diego, USA.Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK. South London and Maudsley NHS Foundation Trust, London, UK.The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, 5290002, Ramat-Gan, Israel. eitan.okun@biu.ac.il. The Paul Feder Laboratory On Alzheimer's Disease Research, Bar-Ilan University, 5290002, Ramat-Gan, Israel. eitan.okun@biu.ac.il. The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel. eitan.okun@biu.ac.il.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33660221

Citation

Illouz, Tomer, et al. "Specific Susceptibility to COVID-19 in Adults With Down Syndrome." Neuromolecular Medicine, 2021.
Illouz T, Biragyn A, Frenkel-Morgenstern M, et al. Specific Susceptibility to COVID-19 in Adults with Down Syndrome. Neuromolecular Med. 2021.
Illouz, T., Biragyn, A., Frenkel-Morgenstern, M., Weissberg, O., Gorohovski, A., Merzon, E., Green, I., Iulita, F., Flores-Aguilar, L., Del Mar Dierssen Sotos, M., De Toma, I., Lifshitz, H., Antonarakis, S. E., Yu, E., Herault, Y., Potier, M. C., Botté, A., Roper, R., Sredni, B., ... Okun, E. (2021). Specific Susceptibility to COVID-19 in Adults with Down Syndrome. Neuromolecular Medicine. https://doi.org/10.1007/s12017-021-08651-5
Illouz T, et al. Specific Susceptibility to COVID-19 in Adults With Down Syndrome. Neuromolecular Med. 2021 Mar 4; PubMed PMID: 33660221.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific Susceptibility to COVID-19 in Adults with Down Syndrome. AU - Illouz,Tomer, AU - Biragyn,Arya, AU - Frenkel-Morgenstern,Milana, AU - Weissberg,Orly, AU - Gorohovski,Alessandro, AU - Merzon,Eugene, AU - Green,Ilan, AU - Iulita,Florencia, AU - Flores-Aguilar,Lisi, AU - Del Mar Dierssen Sotos,Maria, AU - De Toma,Ilario, AU - Lifshitz,Hefziba, AU - Antonarakis,Stylianos E, AU - Yu,Eugene, AU - Herault,Yann, AU - Potier,Marie-Claude, AU - Botté,Alexandra, AU - Roper,Randall, AU - Sredni,Benjamin, AU - Sarid,Ronit, AU - London,Jacqueline, AU - Mobley,William, AU - Strydom,Andre, AU - Okun,Eitan, Y1 - 2021/03/04/ PY - 2021/01/20/received PY - 2021/02/16/accepted PY - 2021/3/4/entrez PY - 2021/3/5/pubmed PY - 2021/3/5/medline KW - COVID-19 KW - Down syndrome KW - Immune dysregulation KW - SARS-CoV-2 KW - Vaccine JF - Neuromolecular medicine JO - Neuromolecular Med N2 - The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer's disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization. SN - 1559-1174 UR - https://www.unboundmedicine.com/medline/citation/33660221/Specific_Susceptibility_to_COVID-19_in_Adults_with_Down_Syndrome. L2 - https://dx.doi.org/10.1007/s12017-021-08651-5 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.